Markets & Investing
Cory Firth is Committed to a Career Empowering Wellbeing – Podcast Episode #44
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Cory Firth, the Co-Founder of Neuma. On his LinkedIn profile, Cory…
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Cory Firth, the Co-Founder of Neuma.
On his LinkedIn profile, Cory describes himself in the following way:
I am a human-impact coach, consultant and entrepreneur who combines a unique set of strategic development & communication tools that empower individuals and organizations in transforming objectives into real world results.
In my consultant role, I work with growth-stage startups, Fortune 500 companies, academic institutions, retreats, advocacy groups and social impact businesses by integrating functional systems design, executive training, implementation alignment, strategic positioning, storytelling and partnership acquisition strategies to support organization-wide goals.
After overcoming a 20+ year battle with depression & suicidal ideation, I have committed my career to a vision where the stigmatization of mental illness is replaced with compassion, transformation and empowered wellbeing. In the last 5 years, I have helped advance groundbreaking mental health research and led regulation-changing projects that have fundamentally changed the way we access psychedelics & other community support services for severe health conditions across Canada, the United States, Central America and the United Kingdom.
Stay tuned for more great Psychedelic Invest Podcast episodes… happening weekly.
If you just found out about the podcast, we encourage you to check out the Psychedelic Invest Podcast page or subscribe to the show on your favorite audio platform to binge and catch up.
The Transcription is Coming Soon
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment